Category: Research/Reports

Researchers who reported in 2018 that the 340B program leads to hospital-physician practice consolidation but probably not to better care or outcomes for low-income patients have released a new 340B study, this time on hospital provision of uncompensated care. The

A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.

The study by health economics and public health researchers at the University of California at Berkeley found that prices paid

Hospitals in the 340B program and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.

Hospital group 340B Health said its Sept. 15 report “finds the three major

Millions of community health center patients could lose access to care if Congress and the Biden administration fail to extend telehealth flexibilities granted during the COVID-19 pandemic, especially for audio-only telehealth, a new survey report warns.

The National Association of

A recent U.S. Supreme Court decision is spurring more states to enact laws banning pharmacy benefit managers (PBMs) from reimbursing 340B pharmacies less for prescription drugs than non-340B providers, health care lawyers say in a new paper.

According to the

Prescription drug sales through the 340B program totaled $38 billion in calendar year 2020, representing 7.2% of overall U.S. sales of $528 billion, Drug Channels blog reports.  Drug Channels is run by pharmaceutical manufacturer consultant Adam Fein, a leading critic